SECTION 1: PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME: Ranibizumab (Lucentis®) (Human) ELISA Kit

PRODUCT CODES: Cat# E4312-100

MANUFACTURER: BioVision, Inc.
DIVISION:
ADDRESS: 155 S. Milpitas Boulevard, Milpitas, CA 95035

EMERGENCY PHONE: 858-373-8066
CHEMTREC PHONE:
OTHER CALLS: 408-493-1800
FAX PHONE: 408-493-1801

SECTION 2: HAZARDS IDENTIFICATION

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
<th>Volume</th>
<th>Safety Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Micro ELISA Plate</td>
<td>--</td>
<td>1</td>
<td>No hazards</td>
</tr>
<tr>
<td>Ranibizumab Standard (25 mg/ml)</td>
<td>Liquid</td>
<td>10 μl</td>
<td>No hazards</td>
</tr>
<tr>
<td>Detection Antibody (2000X)</td>
<td>Liquid</td>
<td>20 μl</td>
<td>No hazards</td>
</tr>
<tr>
<td>Assay Diluent</td>
<td>--</td>
<td>100 μl</td>
<td>No hazards</td>
</tr>
<tr>
<td>TMB substrate (20X) (Avoid light)</td>
<td>Liquid</td>
<td>1 ml</td>
<td>No hazards</td>
</tr>
<tr>
<td>Wash buffer–A (20X)</td>
<td>Liquid</td>
<td>70 ml</td>
<td>No hazards</td>
</tr>
<tr>
<td>Plate sealers</td>
<td>--</td>
<td>2</td>
<td>No hazards</td>
</tr>
</tbody>
</table>

Emergency Overview
OSHA Hazards: No known OSHA hazards
GHS Classification: Not a dangerous substance according to GHS
GHS Label elements, including precautionary statements
Pictogram: none
Signal word: none
Hazard statement(s): none
Precautionary statement(s): none

HMIS Classification
- Health hazard: 0
- Flammability: 0
- Physical hazards: 0

NFPA Rating
- Health Hazard: 0
- Fire: 0
- Reactivity Hazard: 0

Potential Health Effects
- Inhalation: May be harmful if inhaled. May cause respiratory tract irritation.
- Skin: May be harmful if absorbed through skin. May cause skin irritation.
- Eyes: May cause eye irritation.
- Ingestion: May be harmful if swallowed.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

No components need to be disclosed according to the applicable regulations.

SECTION 4: FIRST AID MEASURES

If inhaled: If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact: Wash off with soap and plenty of water.
In case of eye contact: Flush eyes with water as a precaution.
If swallowed: Never give anything by mouth to an unconscious person. Rinse mouth with water.
SECTION 5: FIRE-FIGHTING MEASURES

Condition of flammability: Not flammable or combustible.
Suitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for fire-fighters: Wear self-contained breathing apparatus for firefighting if necessary.
Hazardous combustion products: Hazardous combustion products formed under fire conditions—carbon oxides, nitrogen oxides.

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personal precautions: Avoid dust formation. Avoid breathing vapors, mist, gas, or dust.
Environmental precautions: Do not let product enter drains.
Methods for cleaning up: Sweep up and shovel. Keep in suitable, closed containers for disposal.

SECTION 7: HANDLING AND STORAGE

Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: -20 °C

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

Contains no substances with occupational exposure limit values.
Personal protective equipment
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove’s outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Eye protection
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin and body protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substance, and to the specific workplace. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.
Hygiene measures
General industrial hygiene practice.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Ranibizumab (Lucentis(R) (Human) ELISA Kit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance:</td>
<td>No data available</td>
</tr>
<tr>
<td>pH:</td>
<td>No data available</td>
</tr>
<tr>
<td>Water Solubility:</td>
<td>No data available</td>
</tr>
<tr>
<td>Other Solubility:</td>
<td>No data available</td>
</tr>
<tr>
<td>Specific Gravity (g/ml):</td>
<td>No data available</td>
</tr>
<tr>
<td>Boiling Point (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting Point (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash Point (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Ignition Temperature (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
</tbody>
</table>

SECTION 10: STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Ranibizumab (Lucentis(R) (Human) ELISA Kit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical stability</td>
<td>Stable under recommended storage conditions</td>
</tr>
<tr>
<td>Conditions to avoid:</td>
<td>No data available</td>
</tr>
<tr>
<td>Materials to avoid:</td>
<td>No data available</td>
</tr>
<tr>
<td>Hazardous decomposition products:</td>
<td>No data available</td>
</tr>
</tbody>
</table>
SECTION 11: TOXICOLOGICAL INFORMATION

Ranibizumab (Lucentis®) (Human) ELISA Kit:
Acute toxicity: no data available
Skin corrosion/irritation: no data available
Serious eye damage/eye irritation: no data available
Respiratory or skin sensitization: no data available
Germ cell mutagenicity: no data available

Carcinogenicity:
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

Reproductive toxicity: no data available
Teratogenicity: no data available
Specific target organ toxicity – single exposure (GHS): no data available
Specific target organ toxicity – repeated exposure (GHS): no data available
Aspiration hazard: no data available

Potential Health Effects
Inhalation: May be harmful if inhaled. May cause respiratory tract irritation.
Skin: May be harmful if absorbed through skin. May cause skin irritation.
Eyes: May cause eye irritation.
Ingestion: May be harmful if swallowed.

Signs and Symptoms of Exposure: To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Synergistic effects: no data available
Additional information: RTECS: not available

SECTION 12: ECOLOGICAL INFORMATION

Ranibizumab (Lucentis®) (Human) ELISA Kit:
Persistence and degradability: no data available
Toxicity: no data available
Bioaccumulative potential: no data available
Mobility in soil: no data available
PBT and vPvB assessment: no data available
Other adverse effects: no data available

SECTION 13: DISPOSAL CONSIDERATIONS

Product: Observe all federal, state, and local environmental regulations.
Contaminated packaging: Dispose of as unused product.

SECTION 14: TRANSPORT INFORMATION

Ranibizumab (Lucentis®) (Human) ELISA Kit:
DOT (US): Not dangerous goods.
IMDG: Not dangerous goods.
IATA: Not dangerous goods.

SECTION 15: REGULATORY INFORMATION

Ranibizumab (Lucentis®) (Human) ELISA Kit:
OSHA Hazards: No known OSHA hazards
SARA 302 Components: SARA 302: No chemical in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components: SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title II, Section 313.
SARA 311/312 Hazards: No SARA Hazards
Massachusetts Right To Know Components: No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components: No components are subject to the Pennsylvania Right to Know Act.
New Jersey Right To Know Components: No components are subject to the New Jersey Right to Know Act.
California Prop. 65 Components: This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.
EU regulations: This product is not classified according to the EU regulations.

<table>
<thead>
<tr>
<th>Component</th>
<th>Risk Phrases</th>
<th>Safety Phrases</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SECTION 16: OTHER INFORMATION

DISCLAIMER:
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. BioVision, Inc., shall not be held liable for any damage resulting from handling or from contact with the above product. See reverse side of invoice or packing slip for additional terms and conditions of sale.